Table 3

Model 1: The association of inflammatory sNfL level and fGd+ with MRI atrophy and clinical measures at the 10-year follow-up, corrected for age, sex, DMT use, eTIV, BL T2LC and Gd+ LC*

		Mean inflammatory sNfL level				fGd+				Full model
MRI/clinical measure	N	B	Std. B	95% CI	P value†	B	Std. B	95% CI	P value†	R² adj.	P value
Total GM volume	25	−850.8	−0.399	−1580.218 to –121.416	0.040	91 552.9	0.362	3400.111 to 179 705.771	0.065	0.504	<0.001
Total WM volume	25				NS				NS
Total deep GM volume	25	−140.31	−0.556	−228.417 to −52.198	0.010				NS	0.341	0.004
Thalamus volume	25				NS				NS
Mean Cth	25	−0.003	−0.581	−0.005 to −0.001	0.010				NS	0.308	0.002
logLesion volume‡	28				NS				NS
logLesion count‡	28	0.004	0.498	0.001 to 0.007	0.018				NS	0.220	0.007
EDSS≥4§	31				NS				NS
logT25FW‡	30				NS				NS
logChange in T25FW‡	30				NS				NS
logD9-HPT‡	29	0.004	0.593	0.002 to 0.006	0.004				NS	0.411	0.001
logChange in D9-HPT‡	29				NS				NS
logND9-HPT‡	29				NS				NS
logChange in ND9-HPT‡	29	−0.006	−0.498	−0.010 to −0.001	0.024				NS	0.399	0.002
PASAT	28				NS				NS
Change in PASAT	28				NS				NS
Oral SDMT	28				NS				NS

*Non-significant covariates removed from final model by backward elimination.
†Adjusted p values after controlling the false discovery rate (FDR) for multiple hypothesis testing.
‡Dependent variable log transformed due to non-normality (log-linear transformation).
§Analysed by logistic regression.
adj, adjusted; B, beta; BL, baseline; Cth, cortical thickness; D9-HPT, dominant hand Nine-Hole Peg Test; DMT, disease modifying therapy; EDSS, Expanded Disability Status Scale; eTIV, estimated total intracranial volume; fGd+, fraction of MRI scans with new Gadolinium-enhancing lesion; Gd+, gadolinium-enhancing; GM, grey matter; LC, lesion count; ND9-HPT, non-dominant hand Nine-Hole Peg Test; PASAT, Paced Auditory Serial Addition Test; SDMT, Symbol Digit Modalities Test; sNfL, serum neurofilament light chain; Std, standardised; T25FW, timed 25-foot walk; WM, white matter.